Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Inventory (2018 - 2026)

Agios Pharmaceuticals (AGIO) has disclosed Inventory for 8 consecutive years, with $35.1 million as the latest value for Q1 2026.

  • For Q1 2026, Inventory rose 18.52% year-over-year to $35.1 million; the TTM value through Mar 2026 reached $35.1 million, up 18.52%, while the annual FY2025 figure was $32.9 million, 19.21% up from the prior year.
  • Inventory hit $35.1 million in Q1 2026 for Agios Pharmaceuticals, up from $32.9 million in the prior quarter.
  • Across five years, Inventory topped out at $35.1 million in Q1 2026 and bottomed at $2.5 million in Q1 2022.
  • Average Inventory over 5 years is $20.3 million, with a median of $23.1 million recorded in 2024.
  • Year-over-year, Inventory surged 357.71% in 2023 and then grew 18.52% in 2026.
  • Agios Pharmaceuticals' Inventory stood at $8.5 million in 2022, then soared by 124.63% to $19.1 million in 2023, then skyrocketed by 44.77% to $27.6 million in 2024, then rose by 19.21% to $32.9 million in 2025, then grew by 6.58% to $35.1 million in 2026.
  • According to Business Quant data, Inventory over the past three periods came in at $35.1 million, $32.9 million, and $32.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.